Afatinib in Non-Small Cell Lung Cancer Harboring Uncommon EGFR Mutations Pretreated With Reversible EGFR Inhibitors
DF Heigener, C Schumann, M Sebastian… - The …, 2015 - academic.oup.com
Abstract Background. Afatinib, an irreversible ErbB family blocker, is approved for treatment
of patients with previously untreated non-small cell lung cancer (NSCLC) harboring …
of patients with previously untreated non-small cell lung cancer (NSCLC) harboring …
Afatinib for the Treatment of Non-Small Cell Lung Cancer Harboring Uncommon EGFR Mutations: An Updated Database of 1023 Cases Brief Report
Introduction Previously, we developed a database of 693 patients with NSCLC and
uncommon EGFR mutations treated with afatinib. Here, we provide an update of> 1000 …
uncommon EGFR mutations treated with afatinib. Here, we provide an update of> 1000 …
[HTML][HTML] Afatinib in EGFR TKI-naïve patients with locally advanced or metastatic EGFR mutation-positive non-small cell lung cancer: Interim analysis of a Phase 3b …
F de Marinis, KK Laktionov, A Poltoratskiy, I Egorova… - Lung Cancer, 2021 - Elsevier
Objectives Randomized controlled trials have demonstrated that afatinib is a suitable
treatment option for patients with epidermal growth factor receptor mutation-positive …
treatment option for patients with epidermal growth factor receptor mutation-positive …
Potential for afatinib as an optimal treatment for advanced non-small cell lung carcinoma in patients with uncommon EGFR mutations
I Tanaka, M Morise, Y Kodama, A Matsui… - Lung …, 2019 - lungcancerjournal.info
Uncommon epidermal growth factor receptor (EGFR) mutations in non-small cell lung
cancer (NSCLC) are a heterogeneous group of genetic alterations that produce variable …
cancer (NSCLC) are a heterogeneous group of genetic alterations that produce variable …
Afatinib for the treatment of nsclc with uncommon egfr mutations: A narrative review
Y Jiang, X Fang, Y Xiang, T Fang, J Liu, K Lu - Current Oncology, 2023 - mdpi.com
Afatinib, the world's first irreversible ErbB family (containing four different cancer cell
epidermal growth factor receptors, including EGFR, HER2, ErbB3, and ErbB4) inhibitor, is a …
epidermal growth factor receptors, including EGFR, HER2, ErbB3, and ErbB4) inhibitor, is a …
Clinical activity of afatinib in patients with non–small-cell lung cancer harboring uncommon EGFR mutations: a Spanish retrospective multicenter study
Introduction Uncommon epidermal growth factor receptor (EGFR) mutations (u-EGFRm) are
a heterogeneous group of molecular alterations and have also been reported as …
a heterogeneous group of molecular alterations and have also been reported as …
Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2 …
JCH Yang, LV Sequist, SL Geater, CM Tsai… - The lancet …, 2015 - thelancet.com
Background Most patients with non-small-cell lung cancer tumours that have EGFR
mutations have deletion mutations in exon 19 or the Leu858Arg point mutation in exon 21 …
mutations have deletion mutations in exon 19 or the Leu858Arg point mutation in exon 21 …
Afatinib treatment in a large real‐world cohort of nonsmall cell lung cancer patients with common and uncommon epidermal growth factor receptor mutation
CH Huang, JS Ju, TH Chiu, ACC Huang… - … Journal of Cancer, 2022 - Wiley Online Library
The epidermal growth factor receptor tyrosine kinase inhibitor (EGFR‐TKI) afatinib improves
survival in nonsmall cell lung cancer (NSCLC) patients with EGFR mutation. We analysed …
survival in nonsmall cell lung cancer (NSCLC) patients with EGFR mutation. We analysed …
[HTML][HTML] Afatinib for the treatment of NSCLC harboring uncommon EGFR mutations: a database of 693 cases
JCH Yang, M Schuler, S Popat, S Miura… - Journal of Thoracic …, 2020 - Elsevier
Introduction Limited clinical data are available regarding the efficacy of EGFR tyrosine
kinase inhibitors (EGFR TKIs) in patients with NSCLC harboring uncommon EGFR …
kinase inhibitors (EGFR TKIs) in patients with NSCLC harboring uncommon EGFR …
Experience with afatinib in patients with non-small cell lung cancer progressing after clinical benefit from gefitinib and erlotinib
M Schuler, JR Fischer, C Grohé, S Gütz… - The …, 2014 - academic.oup.com
Abstract Background. Afatinib, an irreversible ErbB family blocker, demonstrated superiority
to chemotherapy as first-line treatment in patients with EGFR-mutated non-small cell lung …
to chemotherapy as first-line treatment in patients with EGFR-mutated non-small cell lung …